Despite the unprecedented success of ibrutinib in lymphoma therapy, the development of ibrutinib resistance due to acquired BTK or PLCγ2 mutations has become a new clinical problem. However, not all resistance is mediated by these mutations and these mechanisms are poorly understood due to a lack of study tools that truly recapitulate this clinical scenario.

中文翻译：

---

MCIR1：一种源自患者的套细胞淋巴瘤细胞系，用于发现伊布替尼耐药的新疗法

尽管依鲁替尼在淋巴瘤治疗中取得了空前的成功，但由于获得性BTK或PLCγ2突变引起的依鲁替尼耐药性的发展已成为一个新的临床问题。然而，并非所有的耐药性都是由这些突变介导的，而且由于缺乏真正概括这种临床情况的研究工具，这些机制也知之甚少。